Written Analysis of a Case, Pricing the EpiPen: This is going to Sting. Please consider the following questions: 1.) What should Heather Bresch do? Why? What risks do you see with this plan of action? 2.) Does the variation in prices across countries seem reasonable. What would happen if Mylan were forced to make its prices more consistent? 3. What changes if any would you make to Mylan's pricing policy? Is there a better way to structure the discounts? 4.What is the biggest risk that Bresch faces? Kindly provide references.